Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Critical Care

Fig. 1

From: Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance

Fig. 1

Unbound steady-state concentrations (mg/L) of piperacillin (a) and tazobactam (b) using higher than licensed dosing regimens (20 g/day [160 mg/mL, 10-h infusion] after a loading dose of 4 g) in critically ill patients with ARC (ClCr ≥ 150 mL/min the first day of antimicrobial therapy). The dotted line indicates underdosing threshold for piperacillin (fixed at 16 mg/L) and tazobactam (fixed at 2 mg/L) [4]. The black circles indicate samples from patients who experienced therapeutic failure [4]

Back to article page